JNJ vs. KO: Two Dividend Kings, One Portfolio Slot — Which Wins?

Both are Dividend Kings with 60+ years of consecutive dividend increases. But they're completely different investments.

Coca-Cola is the ultimate consumer staple — Warren Buffett's crown jewel, built on pricing power and global brand dominance. Johnson & Johnson is a healthcare and medtech powerhouse, restructured post-Kenvue spinoff into a leaner, higher-margin business with a pharmaceutical pipeline that Buffett himself called an asset no one can replicate overnight.

The comparison tools rank #1 and #2 for "JNJ vs KO" because no real editorial comparison exists for this popular question. Here's one.

---

Quick Verdict

JNJ is the healthcare bet: lower starting yield, cheaper P/E valuation historically, and a 62-year streak backed by a pharmaceutical pipeline and MedTech segment. The 2023 Kenvue spinoff removed consumer health (Band-Aid, Tylenol, Neutrogena) and left a sharper, higher-margin core. JNJ is for investors who want diversification into healthcare and believe the market is undervaluing pharma durability.

KO is the pure brand play: Buffett's largest non-financial holding, with unmatched pricing power, international distribution reaching 200+ countries, and 63 consecutive years of dividend increases. KO is for investors who want the simplest, most recession-resistant consumer business in the world — and are willing to pay a premium for it.

The boring truth: For most long-term dividend investors, owning both is the right answer. They rarely move in sync, which gives you sector diversification within your dividend portfolio's conservative wing.

---

Side-by-Side Comparison (As of Q1 2026, Approximate)

| Metric | JNJ (Johnson & Johnson) | KO (Coca-Cola) | |--------|:-----------------------:|:--------------:| | Share Price | ~$158 | ~$67 | | Dividend Yield | ~3.1% | ~2.9% | | P/E Ratio | ~16x | ~25x | | Payout Ratio | ~47% | ~72% | | Dividend Streak | 62 years | 63 years | | Sector | Healthcare (Pharma/MedTech) | Consumer Staples | | 5-Year Revenue CAGR | ~6% | ~7% | | Graham Number (approx.) | ~$82 | ~$18 | | S&P 500 Member | ✅ Yes | ✅ Yes | | Dividend Aristocrat | ✅ Yes | ✅ Yes |

Data approximate as of March 2026. Always verify current figures before investing.

---

Deep Dive: Johnson & Johnson (JNJ)

The Post-Kenvue Story

If you haven't tracked JNJ closely since 2023, the most important thing to know is: the JNJ you're buying today is not the JNJ of five years ago.

In August 2023, Johnson & Johnson completed the spinoff of Kenvue (KVUE) — its entire consumer health segment. Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno — all of it was separated into a standalone publicly traded company. The consumer health business had revenues of roughly $15B annually. It's now gone from JNJ's books.

What remains is a pure-play pharmaceutical and MedTech company. That's not a downgrade — it's arguably a sharper, more defensible version of JNJ. Consumer health brands compete on marketing. Pharmaceuticals compete on patents, clinical data, and FDA relationships. MedTech competes on engineering and hospital relationships. These are higher-margin, higher-moat businesses.

The Pharma Pipeline

JNJ's pharmaceutical segment is anchored by oncology (Darzalex, Erleada), immunology (Stelara, though Stelara faces biosimilar competition), and neuroscience (Spravato). The concern post-2023 was Stelara's patent expiration — a real headwind. The bull case is that JNJ's oncology and next-generation immunology pipeline more than offsets the biosimilar pressure on legacy drugs.

JNJ spends approximately $15B per year on R&D. For context, that's more than most countries' entire pharmaceutical budgets. The pipeline at any given time includes 100+ compounds across Phase 1, 2, and 3 trials. Not all of them work — biotech failure rates are high — but the law of large numbers applies. Big pharma with diversified pipelines tends to find winners.

MedTech: The Underrated Segment

JNJ's MedTech division (cardiovascular devices, orthopedics, surgery) generates roughly $30B annually. It's less exciting than biotech but strategically critical: hospitals replace surgical devices on multi-year cycles, creating recurring revenue that's largely insulated from drug patent cliffs. The aging global population provides a structural tailwind — more joint replacements, more cardiovascular procedures, more surgical volume.

The 62-Year Streak

JNJ has raised its annual dividend for 62 consecutive years as of 2026. That streak runs through the 1970s stagflation, Black Monday 1987, the dot-com crash, the 2008 financial crisis, and COVID-19. The dividend has grown at roughly 6% annually over the past decade — faster than inflation, slow enough to remain sustainable.

At a 47% payout ratio, JNJ retains more than half of earnings to fund R&D, acquisitions, and share buybacks. The dividend is extremely well-covered.

---

Deep Dive: Coca-Cola (KO)

Buffett's Crown Jewel — and Why

Warren Buffett began buying Coca-Cola stock in 1988. Berkshire Hathaway owns roughly 400 million shares — approximately 9.3% of the company — and has not sold a single share since. Buffett has called KO one of his "forever" holdings.

Why? Pricing power. Coca-Cola can raise prices when input costs rise (as it demonstrated aggressively in 2022–2024) and consumers continue buying because the product is habitual, affordable, and globally ubiquitous. A can of Coke costs more than it did 10 years ago. Volume has held steady or grown. That combination — price plus volume resilience — is extraordinarily rare.

The Global Distribution Moat

Coca-Cola operates in over 200 countries and territories. Its distribution network — the trucks, coolers, bottling partnerships, and shelf space relationships built over 130+ years — is functionally irreplaceable. A new beverage company cannot spend its way into that network in a reasonable timeframe. The moat is real and wide.

Approximately 60% of KO's revenue comes from outside North America. That geographic diversification provides a buffer against any single regional economic downturn. It also introduces currency risk — a stronger U.S. dollar compresses reported revenue when foreign currencies weaken — but over 5–10 year periods, that tends to average out.

The Diversification Inside KO

"Coca-Cola" is a brand, not just a product. The company's portfolio includes Sprite, Fanta, Dasani, Smartwater, Minute Maid, Simply Orange, Fairlife, Powerade, and dozens of regional brands. The company has been diversifying away from sugary carbonated beverages for over a decade. Still, Coke Classic and Diet Coke remain the revenue anchors. The question for long-term investors is whether that core can sustain volume as health trends shift — a legitimate but not imminent risk.

The 63-Year Streak

Coca-Cola has raised its dividend for 63 consecutive years, earning its Dividend King status. The yield of approximately 2.9% is modest, but that yield has been compounding for decades. An investor who bought KO in 1988 at Buffett's average cost is collecting well over 50% yield-on-cost today.

KO's payout ratio of ~72% is higher than JNJ's, leaving less retained earnings for reinvestment. But Coke's business model doesn't require heavy capital reinvestment — it generates enormous free cash flow relative to the capex needed to maintain operations.

---

Graham Number Analysis: Which Is Closer to Fair Value?

Benjamin Graham's formula — Graham Number = √(22.5 × EPS × Book Value Per Share) — is designed to identify stocks trading below intrinsic value. Let's apply it to both, with the significant caveat that the Graham Number works best for capital-intensive businesses with tangible assets. Consumer brands (KO) and pharmaceutical companies (JNJ) have characteristics that strain the formula.

Johnson & Johnson: With approximate EPS of ~$10 and book value per share of ~$30 (post-Kenvue restructuring), the Graham Number works out to approximately √(22.5 × 10 × 30) = √6,750 ≈ $82.

At ~$158/share, JNJ trades at roughly 93% above its Graham Number — meaning it's priced at roughly double Graham's simple fair value estimate. That looks expensive on its face. But the Graham Number doesn't capture JNJ's pharmaceutical patents, regulatory approvals, R&D pipeline, or brand value — all of which are real economic assets that don't appear on the balance sheet. JNJ is a good candidate for the Graham Calculator but should be analyzed with that limitation in mind.

Coca-Cola: This is where the Graham Number really breaks down. KO has been buying back shares and paying dividends for decades, which has dramatically reduced book value per share (now approximately $5–6). With EPS of approximately $2.70, the Graham Number works out to approximately √(22.5 × 2.70 × 5.5) ≈ √333 ≈ $18.

At ~$67/share, KO trades at roughly 270% above its Graham Number. This isn't a sign of a bubble — it's a sign that the Graham Number is the wrong tool for an asset-light, brand-driven business that generates exceptional cash returns on minimal physical capital. KO's "book value" is a fictionally low number that misses the multi-hundred-billion dollar value of its global distribution network and brand equity.

The takeaway: On pure Graham Number math, JNJ is significantly closer to fair value than KO. JNJ also trades at a lower P/E (~16x vs. ~25x) — a pattern that has held historically, with JNJ consistently pricing at a discount to Coca-Cola on standard earnings multiples. For value-oriented investors, JNJ is the more attractively priced of the two by conventional measures.

Use the Graham Calculator to run both with your own inputs and margin of safety requirements.

---

Who Should Pick JNJ?

Profile 1: The Healthcare Under-Allocator Your dividend portfolio is 80% consumer staples and utilities. You want more sector diversification without sacrificing dividend quality. JNJ is the cleanest way to add healthcare exposure with a 62-year dividend track record behind it. Its pharma-and-medtech focus gives you differentiated exposure to aging demographics and healthcare spending growth.

Profile 2: The Value Investor You screen on P/E and P/B. JNJ's ~16x P/E is significantly cheaper than KO's ~25x and cheaper than the broader S&P 500. You want to own quality businesses at reasonable prices, not pay a premium for pure brand reputation. JNJ's post-Kenvue valuation discount reflects lingering uncertainty about the pharma pipeline — which you see as opportunity, not risk.

Profile 3: The Dividend Safety Maximizer Your primary concern is payout safety. JNJ's 47% payout ratio is among the lowest of any Dividend King — it retains more than half of earnings. Even if earnings fell 30%, the dividend would still be covered. You're building a portfolio that can survive recessions without cuts, and you want maximum FCF coverage.

---

Who Should Pick KO?

Profile 1: The Recession-Proof Portfolio Builder You're not trying to maximize returns — you're trying to own businesses that perform in all weather. People drink Coke (or water, or juice) regardless of the economic cycle. KO's revenue and earnings are among the most recession-resistant of any large company in history. You want something that lets you sleep during bear markets.

Profile 2: The Long-Term Compounder You're not retiring for 20+ years. You want a business that Buffett can hold forever and so can you. KO's pricing power and global distribution compound quietly over decades. The starting yield of ~2.9% is modest, but the yield-on-cost in 20 years at KO's historical growth rate is substantially higher. You're buying the growth, not just the coupon.

Profile 3: The Consumer Staples Believer You think the next decade will reward boring, predictable businesses over speculative growth. Consumer staples — especially companies with global pricing power — tend to outperform in late-cycle and recessionary environments. You want KO as your anchor allocation in that thesis.

---

The Boring Truth: You Should Probably Own Both

This is a common false choice. JNJ and KO don't compete for the same earnings drivers:

• JNJ's performance is driven by FDA approvals, drug pricing, and medical device adoption.
• KO's performance is driven by consumer spending, beverage trends, and global currency movements.

These are largely uncorrelated. In a healthcare disruption year (unexpected drug failure, regulatory action), KO would likely hold steady. In a consumer spending downturn (recession, consumer staple rotation selling), JNJ's healthcare revenues wouldn't skip a beat.

Together, they give you:

• Two Dividend Kings with combined 125 years of consecutive increases
• Healthcare + consumer staples sector exposure
• Combined yield of ~3.0% at current prices
• Two of the most durable businesses in the history of public markets

Example: $10,000 invested equally ($5,000 each)

• JNJ at 3.1% yield → ~$155/year
• KO at 2.9% yield → ~$145/year
• Combined: ~$300/year from two of the most reliable dividend payers alive

That's not exciting. That's the point. The dividend from this $10K position has grown every single year for over six decades running — and both companies have shown every indication of continuing that tradition.

---

Run the Numbers Yourself

Want to calculate the Graham Number for JNJ or KO with current data? Use the Graham Calculator. Input current EPS and book value per share for your own margin-of-safety analysis.

Looking for the full universe of Dividend Kings and Aristocrats? The Dividend Aristocrats page shows all 66 current Aristocrats with yield and growth data. For a screener that filters by yield, payout ratio, and Graham margin-of-safety, try the Stock Screener.

---

The Bottom Line

| | JNJ | KO | |--|:---:|:--:| | Cheaper on P/E | ✅ | | | Closer to Graham Number | ✅ | | | Better payout ratio coverage | ✅ | | | More recession-resistant revenues | | ✅ | | Buffett's forever holding | | ✅ | | Simpler business model | | ✅ | | Healthcare/diversification upside | ✅ | | | Pure consumer staple exposure | | ✅ | | Longer dividend streak | | ✅ (63 vs 62 yrs) |

If you're a value investor who screens on P/E and payout safety: JNJ is the better buy right now. If you want the simplest, most recession-proof business on earth: KO is your pick. If you're building a portfolio to last 20+ years: own both, stop overthinking it.

---

This article is for informational purposes only and does not constitute financial advice. Always do your own research before investing.